This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Quark Pharmaceuticals, Inc.
Drug Names(s): QPI-1007
Description: QPI-1007 is a neuroprotective agent with a proprietary siRNA structure in development for the treatment of non-arteritic anterior ischemic optic neuropathy (NAION). The drug is designed to temporarily inhibit the expression of caspase 2.
Preclinical studies have demonstrated a robust neuroprotective effect of QPI-1007 when administered immediately after injury induced by optic nerve crush or axotomy in two models of retinal ganglion cell (RGC) death as well as in a rat intraocular pressure (IOP) elevation model in which the drug was injected 2 weeks after IOP elevating operation. QPI-1007 has been evaluated in several preclinical models of ocular neuroprotection, and has been shown in these models to protect retinal ganglion cells from injury-induced apoptosis.
Deal Structure: QPI-1007 was developed internally by Quark in collaboration with BioSpring GmbH.
Nitto Denko and Quark
In July 2010, Nitto Denko and Quark announced the initiation of a collaboration and license agreement for the development of siRNA therapeutics for the treatment of fibrotic diseases. These results support the further evaluation of QPI-1007 as a potential novel treatment for glaucoma.
Biocon and Quark
In December 2013, Biocon and Quark announced that they have entered into a licensing and collaboration agreement for the development of a range of siRNA (small interfering RNA) based novel therapeutics. This collaboration will enable Biocon to co-develop, manufacture and commercialize QPI-1007 for ophthalmic conditions, for India and other key markets. Biocon will have access to Quark's siRNA technology platform that can be leveraged for the development of novel therapeutics for various unmet medical needs. Financial terms were not disclosed.
Partners: Nitto Denko Corporation Biocon, Ltd.
Additional information available to subscribers only: